XOMA (NASDAQ:XOMA) Downgraded by StockNews.com to Sell

XOMA (NASDAQ:XOMA) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Separately, HC Wainwright reiterated a “buy” rating and issued a $123.00 price objective on shares of XOMA in a report on Tuesday.

XOMA Price Performance

Shares of XOMA opened at $25.74 on Wednesday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The firm has a market cap of $303.29 million, a PE ratio of -7.40 and a beta of 0.92. The firm’s 50 day moving average price is $29.20 and its 200 day moving average price is $27.94. XOMA has a twelve month low of $18.57 and a twelve month high of $35.00.

Insider Buying and Selling at XOMA

In other news, CEO Owen Hughes sold 21,881 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the sale, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

Several hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its position in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after buying an additional 795 shares during the period. Rhumbline Advisers increased its position in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after acquiring an additional 1,334 shares during the period. Barclays PLC raised its stake in XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares during the last quarter. Ellsworth Advisors LLC bought a new stake in XOMA in the 3rd quarter valued at $516,000. Finally, Bank of New York Mellon Corp grew its position in XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares during the last quarter. Institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.